Loading...
Market
Which major pharmaceutical company will partner with Sungkyunkwan University for DDL-920 development by March 31, 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Press releases from pharmaceutical companies and Sungkyunkwan University
Story
New Alzheimer's Treatment with DDL-920 Flips Memory Back On
Aug 9, 2024, 06:28 PM
Researchers at Sungkyunkwan University in South Korea have developed a novel approach to improve Alzheimer's treatment using light-activated exosome protein delivery. Additionally, a new molecular compound named DDL-920 has been created to enhance memory function in Alzheimer's patients. This compound works by inhibiting the action of GABA, a chemical messenger that dampens gamma oscillations in fast-firing structures known as parvalbumin neurons. This approach shifts focus from combating plaques linked to Alzheimer's to boosting electrical oscillations in the brain, showing promise in reversing Alzheimer's symptoms. The new compound effectively flips memory back on in Alzheimer's cases.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%